StreetAlpha
13F holdings · Q3 2026

Diadema Partners

Morristown, NJ · files as Diadema Partners LP
Know the moment Diadema Partners filesYou follow Diadema Partners An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 2026172

Diadema Partners reported 81 stocks worth $220M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are UTHR (11.4%), COGT (9.3%) and ABVX (8.1%). Compared with Q2 2026, the fund opened new positions in BBIO, REPL and LQDA, added to COGT, ABVX and VRDN, trimmed UTHR, BMRN and RVMD and sold out of AMGN, NVO and RLAY.

Latest filing: what Diadema Partners did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
35 new16 added26 trimmed31 sold outBought about $60.7M · sold about $138M
New 35
See all 35 →
Added 16
See all 16 →
Trimmed 26
See all 26 →
Sold out 31
See all 31 →

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$220M−27.0% vs last quarter · $731M including options
Stocks held8135 new · 31 sold out
Top 5 weight42.3%fairly concentrated
Turnover90%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
UTHR
United Therapeutics Corp Del
$25M11.4%46K−6,767 (−13%)4 of 8
2
COGT
Cogent Biosciences Inc
$20.6M9.3%642K+148K (+30%)8 of 8
3
ABVX
Abivax SA
$17.7M8.1%178K+15K (+9%)5 of 8
4
BMRN
Biomarin Pharmaceutical Inc
$15.3M7.0%255K−57K (−18%)7 of 8
5
RVMD
Revolution Medicines Inc
$14.4M6.5%70K−69K (−50%)6 of 8
6
VKTX
Viking Therapeutics Inc
$14.1M6.4%433K−8,642 (−2%)7 of 8
7
BBIO
Bridgebio Pharma Inc
$6.8M3.1%104KNew position3 of 8
8
IMCR
Immunocore Hldgs PLC
$6.7M3.0%222K−33K (−13%)7 of 8
9
FDMT
4D Molecular Therapeutics in
$6M2.7%421K−150K (−26%)2 of 8
10
VRDN
Viridian Therapeutics Inc
$5.3M2.4%257K+157K (+157%)6 of 8
🔒 71 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
AMGN
Amgen Inc
$37.2M103K
NVO
Novo-Nordisk A S F
$4.8M100K
RLAY
Relay Therapeutics Inc
$4.3M231K
ZYME
Zymeworks Inc
$3.7M142K
BIOA
Bioage Labs Inc
$3.6M146K

🔒 Free account: see all 30.

Options

valued at the underlying shares
StockTypeValueSharesChange
VKTX
Viking Therapeutics Inc
Put$44.4M1.4M+1,011,400
BMY
Bristol Myers Squibb Co
Call$37.4M600K0
VKTX
Viking Therapeutics Inc
Call$37.1M1.1M−81,400
KOD
Kodiak Sciences Inc
Put$28.2M297K+150,100
UTHR
United Therapeutics Corp Del
Call$25.7M48K+47,500

🔒 Free account: see all 20.

Reported value

last 8 quarters
$88.7MQ4 '24
$125MQ1 '25
$161MQ2 '25
$144MQ3 '25
$168MQ4 '25
$242MQ1 '26
$301MQ2 '26
$220MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Diadema Partners 13F FAQ

What does Diadema Partners own?

Diadema Partners reported 81 stocks worth $220M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are UTHR (11.4%), COGT (9.3%) and ABVX (8.1%). The table above lists every position in the filing (the top 10 without an account).

What did Diadema Partners buy and sell in Q3 2026?

Compared with Q2 2026: 35 new positions, 16 added to, 26 trimmed and 31 sold out. New positions include BBIO, REPL and LQDA. It sold all of AMGN, NVO and RLAY.

When will Diadema Partners file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Diadema Partners's portfolio worth?

The Q3 2026 filing reports $220M in US stocks ($731M including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.